- |||||||||| Increlex (mecasermin) / Ipsen
Enrollment change, Trial withdrawal, Trial primary completion date: Increlex Treatment of Children With Chronic Liver Disease and Short Stature (clinicaltrials.gov) - Jul 15, 2016 P=N/A, N=0, Withdrawn, Trial primary completion date: May 2016 --> May 2017 N=20 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2013 --> Oct 2011
- |||||||||| sorafenib / Generic mfg.
Enrollment change, Trial primary completion date: Sorafenib for Hepatopulmonary Syndrome (clinicaltrials.gov) - Jul 7, 2016 P2, N=30, Recruiting, Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jul 2016 N=50 --> 30 | Trial primary completion date: Jun 2016 --> Jun 2017
- |||||||||| oxaliplatin / Generic mfg., erlotinib / Generic mfg., gemcitabine / Generic mfg.
Enrollment closed, Metastases: Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer (clinicaltrials.gov) - Jun 29, 2016 P1, N=28, Active, not recruiting, Phase classification: P1/2 --> P1b/2 Completed --> Active, not recruiting
- |||||||||| Trial completion, Enrollment change, Trial primary completion date: Hepatitis A Vaccination in the Elderly (clinicaltrials.gov) - Jun 29, 2016
P=N/A, N=60, Completed, Initiation date: Aug 2014 --> Aug 2015 | Trial primary completion date: Aug 2015 --> Sep 2016 Recruiting --> Completed | N=120 --> 60 | Trial primary completion date: Nov 2011 --> Jul 2015
- |||||||||| Enrollment closed, Enrollment change, Trial primary completion date: Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies (clinicaltrials.gov) - Jun 24, 2016
P=N/A, N=13, Active, not recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Nov 2016 Recruiting --> Active, not recruiting | N=60 --> 13 | Trial primary completion date: Sep 2014 --> Jul 2016
- |||||||||| Trial primary completion date: Gilead Sustained Virologic Response (SVR) Registry (clinicaltrials.gov) - Jun 23, 2016
P=N/A, N=7000, Enrolling by invitation, Trial primary completion date: Jul 2019 --> Oct 2020 Trial primary completion date: Jul 2019 --> Oct 2020
- |||||||||| Enrollment closed, Trial primary completion date, Adherence: Intervention to Improve HCV Treatment Uptake and Adherence in HIV/HCV Coinfection (clinicaltrials.gov) - Jun 17, 2016
P=N/A, N=85, Active, not recruiting, Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Jan 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Dec 2016
- |||||||||| Enrollment change, Trial initiation date, Trial withdrawal, Trial primary completion date: Resveratrol and Human Hepatocyte Function in Cancer (clinicaltrials.gov) - Jun 15, 2016
P1/2, N=0, Withdrawn, Recruiting --> Completed | N=150 --> 71 | Trial primary completion date: Dec 2015 --> May 2016 N=80 --> 0 | Initiation date: Dec 2016 --> Dec 2015 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jul 2017 --> Jun 2016
- |||||||||| Trial completion, Trial primary completion date, Gold standard: Renal Function Determination in Patients With Liver Cirrhosis (clinicaltrials.gov) - Jun 10, 2016
P=N/A, N=92, Completed, Recruiting --> Completed | N=240 --> 88 | Trial primary completion date: Feb 2015 --> Jun 2016 Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Dec 2015
|